Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017

GlobeNewswire February 23, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada

MarketWire Canada February 22, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada

GlobeNewswire February 22, 2017

Alimera Sciences Announces the Reimbursement of ILUVIEN® in Italy

GlobeNewswire February 6, 2017

Technical Reports on Healthcare Stocks -- Teva Pharma, Endo, Ionis Pharma, and Alimera Sciences

PR Newswire November 30, 2016

Alimera Sciences Announces Third Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire November 2, 2016

Alimera Sciences Begins Selling ILUVIEN® in the Middle East

GlobeNewswire October 26, 2016

Alimera Sciences to Report Third Quarter 2016 Financial Results on November 2, 2016

GlobeNewswire October 25, 2016

Alimera Sciences Strengthens Financial Position

GlobeNewswire October 20, 2016

Research Reports Initiation on Healthcare Stocks -- Alimera Sciences, Biostar Pharma, LifePoint Health, and Quorum Health

PR Newswire October 14, 2016

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 16, 2016

Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress

GlobeNewswire September 6, 2016

Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock

GlobeNewswire August 16, 2016

Alimera Sciences Prices Public Offering of Common Stock

GlobeNewswire August 11, 2016

Alimera Sciences Proposes Public Offering of Common Stock

GlobeNewswire August 10, 2016

Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting

GlobeNewswire August 9, 2016

20 Biggest Mid-Day Losers For Thursday

Benzinga.com  August 4, 2016

Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update

GlobeNewswire August 3, 2016

Mid-Morning Market Update: Markets Mostly Higher; Caterpillar Tops Q2 Views

Benzinga.com  July 26, 2016

Alimera Sciences Pre-Announces Record Second Quarter 2016 Revenue

GlobeNewswire July 26, 2016